Project Grant R01AA032711
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $498,002 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Illinois to conduct a study aimed at increasing alcohol abstinence in young adults with alcohol use disorder (AUD). The overall goals of this 3-year project are to: (1) test the efficacy of combining contingency management (CM) with problem-solving therapy (CM-PST) versus CM alone in a 2-arm pilot randomized controlled trial, and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- This federal Project Grant award of $423,313, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to develop an AI-driven platform for identifying potential therapeutic candidates for Alcohol Use Disorder (AUD). The award to Biosymetrics Inc., based in Huntington, NY, will leverage the company's existing AI-based zebrafish behavioral screening technology and AUD-specific experimental findings to create a commercial...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $3,168,729 to New York University to conduct a collaborative research project titled "A Translational Approach for Novel Precision Medicine Models." The project aims to identify novel molecular targets and mechanisms of treatment responses in alcohol use disorder (AUD) based on the role of mitochondrial metabolism and epigenetic...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $901,666 Project Grant to Research Triangle Institute (RTI International) to develop small molecule modulators of the RXFP3 receptor as potential therapeutic agents for alcohol use disorder (AUD). The project aims to further optimize and evaluate the effectiveness of the RXFP3 negative allosteric modulators (NAMs) RLX-33 and RLX-79 in animal models of alcohol...
- This federal Project Grant award of $2,552,568.00, awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) program, supports research to investigate the relationship between stress-induced neuroadaptations in the insula-BNST pathway and subsequent alcohol use disorder (AUD)-related behavior. The project, conducted by Wake Forest University Health Sciences, aims to elucidate how stress activation of AUD-associated...
- This Project Grant award, totaling $755,539, was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The funding will support research conducted by Emory University to evaluate the real-world utilization, effectiveness, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a treatment for alcohol use disorder (AUD). The project aims to leverage administrative claims data and linked electronic health records...
- This Project Grant award, totaling $560,108.00 and spanning September 15, 2025 to August 31, 2030, was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The purpose of the project is to investigate the neurocognitive mechanisms that promote resilience to alcohol use disorder (AUD) in individuals with a family history of AUD. Specifically, the research will examine how attentional abilities may...
- This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...
This Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which falls under the federal Alcohol Research Programs (CFDA 93.273). The $692,723 award will support a double-blind, placebo-controlled clinical trial to test whether the drug suvorexant can be used as a novel therapeutic for alcohol use disorder (AUD) and stress-related drinking. The 5-year project, running from September 2025 through August 2030, will be conducted by researchers at The Ohio State University. The study aims to simultaneously assess the treatment's efficacy, mechanisms, and predictors of response in 250 treatment-seeking individuals with current AUD. This research builds on prior studies by the Principal Investigators that demonstrated suvorexant's potential to reduce exaggerated stress reactivity and heavy drinking days in non-treatment seeking individuals with AUD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $692.7k | 9/18/25 |